Across TCGA pan-cancer cohorts, FAM180A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM180A data layer compared with 18 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM180A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM180A expression acts as an unfavorable survival marker.
LUAD, PAAD, and COAD are the cancer types where FAM180A Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.